A Dose Ranging Study to Examine TDS-Testosterone 5%

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-06-30

Study Completion Date

2027-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a continuation of previous studies done in healthy volunteers to prove the efficacy of delivering Testosterone, the male hormone, rapidly across intact skin in s series of doses from low to high in men with low-to-no natural testosterone production to measure their response to the varying doses. The results of this study will inform further studies which will be longer in length, as to the starting doses. The study will be conducted in London, U.K. at the Advanced Therapies Centre, The London Clinic.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Product Transference Study of Testagen™ TDS®-Testosterone

NCT02733133

Hypogonadotropism

ENROLLING_BY_INVITATION PHASE2

A Clinical Study to Evaluate the Pharmacokinetics of Testosterone Gel Using an Applicator

NCT01464879

Hypogonadal Males

COMPLETED PHASE2

Efficacy, Pharmacokinetics and Safety of Testosterone

NCT01370369

Testicular Hypogonadism

COMPLETED PHASE2

Phlebotomy Study of Testosterone Undecanoate

NCT02670343

Hypogonadism

COMPLETED PHASE1/PHASE2

Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men

NCT01104246

Hypogonadism

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

48 Patients will be enrolled following 2 independent verifying blood tests of their diagnosis of Hypogonadism. there will be 4 cohorts of 12 subjects, each receiving doses of the trail materials, titrated by means of number of sprays applied. Doses will range from 10 to 70 mgs Testosterone.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypogonadotropism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Forearm dose

Half of Ss will receive their dose of Testosterone on the inner aspects of their forearms.

Group Type ACTIVE_COMPARATOR

Testosterone

Intervention Type DRUG

10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.

Pump Sprayer

Intervention Type DEVICE

A dose of product solution is delivered by means of a metered pump spray.

Chest Dose

Half of Ss will receive their dose of Testosterone on the chest.

Group Type ACTIVE_COMPARATOR

Testosterone

Intervention Type DRUG

10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.

Pump Sprayer

Intervention Type DEVICE

A dose of product solution is delivered by means of a metered pump spray.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Testosterone

10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.

Intervention Type DRUG

Pump Sprayer

A dose of product solution is delivered by means of a metered pump spray.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Hypogonadal Male subjects - morning testosterone level ≤300 ng/dL (10.4 ng/L).
2. 18 and 75 years of age, inclusive.
3. The subject is willing and able to read, understand the Subject Information Sheet and provide written informed consent.
4. The subject has a body mass index (BMI) within 18-30 kg/m2.
5. The subject is in otherwise good health as determined by medical history and physical examination.
6. The subject is a non-smoker.
7. The subject must agree to comply with the placement of an indwelling catheter on two separate occasions and the drawing of blood samples for the pharmacokinetic assessments.
8. The subject is willing and able to comply with all testing and requirements defined in the protocol.
9. The subject is willing and able to return to the study site for all visits.

Exclusion Criteria

1. The subject has any relevant deviations from normal in physical examination, electrocardiogram (ECG), or clinical laboratory tests, as evaluated by the investigator, particularly an elevated PSA reading \>4.0 ng/ml or ALT and AST greater than 2 times the upper limit of normal, clinically significant anemia (hematocrit \<35%) or renal dysfunction (creatinine \>2mg/dL), active deep vein thrombosis, thromboembolic disorders or history of these conditions.
2. The subject has had a clinically significant illness within 30 days preceding entry into this study.
3. The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease.
4. The subject has a known allergy or history of hypersensitivity to Testosterone or similar compounds.
5. The subject has used any prescription medication within 14 days or over-the-counter (OTC) medication or alcohol within 48 hours of dosing or intends to use any prescription or OTC medication during the study that may interfere with the evaluation of study medication.
6. The subject has donated or lost a significant volume of blood (\>450 mL) within four (4) weeks of the study, and their haemoglobin concentration and haematocrit have not returned to within 5% of normal.
7. The subject has a Hematocrit level \> 51%
8. The subject has a history of substance abuse or a current positive urine drug screen or urine alcohol test.
9. Alcohol consumption greater than community norms (i.e. more than 21 standard drinks per week for males).
10. Subjects who have received an investigational drug or have used an investigational device in the 30 days prior to study entry.
11. Subjects with an American Urological Association System Index for Prostatism score greater than 7
12. Subjects with a history of prostate or breast carcinoma.
13. Subjects with prostatic mass on screening physical examination.
14. Subjects with a history of significant skin disease.
15. Subjects with a history of sleep apnea.
16. Subject with a partner with a history of breast cancer.
17. Subject with a partner of child bearing potential who is not willing to use adequate contraception for the duration of the trial.
18. Subject whose partner is pregnant.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No